Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670266 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
A Phase 1 study, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01670266 is a Phase 1 study that has completed, run by Ono Pharma USA. The registered enrollment target is 60 participants.
The verdict
NCT01670266, a Phase 1 study, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG). The secondary objectives are to evaluate Pharmacodynamics (PD) and to characterize the pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to compare its tolerability following morning and evening dosing.
Interventions
- DRUG Placebo
- DRUG ONO-9054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670266
The ClinicalTrials.gov registry entry for NCT01670266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01670266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670266 about?
NCT01670266 is a clinical study titled "Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma". The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG). The secondary objectives are to evaluate Pharmacodynamics (PD) and to charact...
What is the current status of trial NCT01670266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-08.
What interventions are being tested in trial NCT01670266?
The interventions under investigation include: Placebo (DRUG), ONO-9054 (DRUG).
Who is sponsoring clinical trial NCT01670266?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.